Ramin Ansari
Neurology · Frisco, TXNPI 1801048285
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $34,813 of the $42,629 with a category attached, or 81.7%. It is spread thinly across 60 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations. Among neurology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,376 payments — averaging $30.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$7K
- AbbVie$5K
- Livanova USA, Inc.$2K
- UCB, Inc.$2K
- Biogen$2K
- Teva Pharmaceuticals USA, Inc.$2K
- plus $23K from 54 others
Across 8 payments — averaging $99,430 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$762K
- Amgen$33K
What the payments were for
- Speaking & faculty fees$5,24312%
- Travel & lodging$2,2205%
- Food & beverage$34,81382%
- Education$3521%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KISUNLA$5,200
- VNS Therapy$1,752
- UBRELVY$1,103
- NURTEC ODT$747
- QULIPTA$624
- Mavenclad$573
- XCOPRI$480
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$393
- AUSTEDO$336
- NOURIANZ$254
- BRIUMVI$252
- VYVGART$246
- Leqembi$237
- Austedo XR$231
- AIMOVIG$226
- Fintepla$226
- Gamunex-C$163
- DYSPORT$142
- UPLIZNA$130
- NUPLAZID$125
How this compares
$42,629 in reported general payments places this provider in the 90th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 23 | $187,804 |
| RebifInterferon Beta-1a/Albumin | 13 | $158,316 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 13 | $149,265 |
| NuplazidPimavanserin Tartrate | 23 | $111,940 |
| VumerityDiroximel Fumarate | 11 | $106,540 |
| CopaxoneGlatiramer Acetate | 17 | $93,961 |
| UbrelvyUbrogepant | 46 | $79,407 |
| QuliptaAtogepant | 57 | $67,810 |
| Nurtec OdtRimegepant Sulfate | 40 | $64,953 |
| Aimovig AutoinjectorErenumab-Aooe | 57 | $54,625 |
| RexultiBrexpiprazole | 25 | $41,959 |
| EpidiolexCannabidiol (Cbd) | 26 | $31,152 |
| XcopriCenobamate | 17 | $27,124 |
| RytaryCarbidopa/Levodopa | 39 | $25,545 |
| Emgality PenGalcanezumab-Gnlm | 21 | $20,976 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $811 | $187,80423 claims |
| EMD Serono, Inc.Rebif | $1,415 | $158,31613 claims |
| AbbVieUbrelvy, Qulipta | $4,668 | $147,217103 claims |
| Acadia Pharmaceuticals IncNuplazid | $682 | $111,94023 claims |
| BiogenVumerity | $1,869 | $106,54011 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $1,688 | $93,96117 claims |
| PfizerNurtec Odt | $1,042 | $64,95340 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $208 | $41,95925 claims |
| SK Life Science, Inc.Xcopri | $1,173 | $27,12417 claims |
| Amneal Pharmaceuticals LLCRytary | $151 | $25,54539 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,246 neurology providers in Texas.
Other neurology in Frisco
- Aimee GarzaFrisco$201K
- Ann BassSan Antonio$1.7M
- William OndoHouston$1.4M
- Nirav PavasiaDallas$1.4M
- Mirla AvilaLubbock$1.3M
- Michael SoileauGeorgetown$1.2M
- Pankaj SatijaHouston$1.1M
- Annette HowardHouston$826K
- Benjamin GreenbergDallas$773K
- Annette OkaiPlano$730K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.